BioCentury | Nov 18, 2019
Clinical News

Karuna quintuples in value as schizophrenia combo clears Phase II bar

...receptor M1 (CHRM1; HM1) and M4, with trospium chloride, a generic antagonist of M2 and M3...
...receptor M1; CHRM2 (H2) - Muscarinic acetylcholine receptor M2; CHRM3 (HM3) - Muscarinic acetylcholine receptor M3...
BioCentury | Aug 29, 2019
Product Development

Pharmas want ICH to streamline toxicity requirements for severe diseases

...took FDA nine years to transition from more conservative approach as laid out in ICH M3...
BioCentury | May 2, 2019
Company News

Management tracks: Akero, NIH, Arcus

...was COO of Nohla Therapeutics Inc. (Seattle, Wash.). Neurodegenerative disease company Athira Pharma Inc. (formerly M3...
BioCentury | Apr 26, 2019
Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

...efficacy in CNS disorders, by combining it with trospium chloride, an antagonist of M2 and M3...
...receptor M1; CHRM2 (H2) - Muscarinic acetylcholine receptor M2; CHRM3 (HM3) - Muscarinic acetylcholine receptor M3...
BioCentury | Apr 5, 2019
Company News

FDA approves Circassia's COPD treatment, AZ gets $20M milestone

...associated with COPD, including chronic bronchitis and emphysema, is an inhalable long-acting, selective M2 and M3...
BioCentury | Mar 18, 2019
Financial News

Karuna looks past schizophrenia with $68M series B

...receptor M1; CHRM2 (H2) - Muscarinic acetylcholine receptor M2; CHRM3 (HM3) - Muscarinic acetylcholine receptor M3...
BioCentury | Aug 17, 2018
Clinical News

FDA accepts applications for Circassia COPD products Duaklir, Tudorza

...associated with COPD, including chronic bronchitis and emphysema, is an inhalable long-acting, selective M2 and M3...
BioCentury | Aug 8, 2018
Distillery Therapeutics

Neurology

...Norgine B.V. market Emselex darifenacin, a CHRM3 antagonist, to treat OAB. TARGET/MARKER/PATHWAY: Muscarinic acetylcholine receptor M3...
...Fraser J. Sim, University at Buffalo, Buffalo, N.Y. email: fjsim@buffalo.edu Hongjiang Li University at Buffalo Muscarinic acetylcholine receptor M3...
BioCentury | Aug 3, 2018
Finance

Karuna’s CNS double play

...acetylcholine receptor M1 (CHRM1; HM1) and M4, with trospium chloride, an antagonist of M2 and M3...
...chloride Karuna Pharmaceuticals Inc. Muscarinic acetylcholine receptor M1 (CHRM1) (HM1) Muscarinic acetylcholine receptor M2 (CHRM2) (HM2) Muscarinic acetylcholine receptor M3...
BioCentury | Aug 3, 2018
Financial News

Karuna raises $42M series A

...Co. Karuna Pharmaceuticals Inc. Muscarinic acetylcholine receptor M1 (CHRM1) (HM1) Muscarinic acetylcholine receptor M2 (CHRM2) (HM2) Muscarinic acetylcholine receptor M3...
Items per page:
1 - 10 of 174
BioCentury | Nov 18, 2019
Clinical News

Karuna quintuples in value as schizophrenia combo clears Phase II bar

...receptor M1 (CHRM1; HM1) and M4, with trospium chloride, a generic antagonist of M2 and M3...
...receptor M1; CHRM2 (H2) - Muscarinic acetylcholine receptor M2; CHRM3 (HM3) - Muscarinic acetylcholine receptor M3...
BioCentury | Aug 29, 2019
Product Development

Pharmas want ICH to streamline toxicity requirements for severe diseases

...took FDA nine years to transition from more conservative approach as laid out in ICH M3...
BioCentury | May 2, 2019
Company News

Management tracks: Akero, NIH, Arcus

...was COO of Nohla Therapeutics Inc. (Seattle, Wash.). Neurodegenerative disease company Athira Pharma Inc. (formerly M3...
BioCentury | Apr 26, 2019
Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

...efficacy in CNS disorders, by combining it with trospium chloride, an antagonist of M2 and M3...
...receptor M1; CHRM2 (H2) - Muscarinic acetylcholine receptor M2; CHRM3 (HM3) - Muscarinic acetylcholine receptor M3...
BioCentury | Apr 5, 2019
Company News

FDA approves Circassia's COPD treatment, AZ gets $20M milestone

...associated with COPD, including chronic bronchitis and emphysema, is an inhalable long-acting, selective M2 and M3...
BioCentury | Mar 18, 2019
Financial News

Karuna looks past schizophrenia with $68M series B

...receptor M1; CHRM2 (H2) - Muscarinic acetylcholine receptor M2; CHRM3 (HM3) - Muscarinic acetylcholine receptor M3...
BioCentury | Aug 17, 2018
Clinical News

FDA accepts applications for Circassia COPD products Duaklir, Tudorza

...associated with COPD, including chronic bronchitis and emphysema, is an inhalable long-acting, selective M2 and M3...
BioCentury | Aug 8, 2018
Distillery Therapeutics

Neurology

...Norgine B.V. market Emselex darifenacin, a CHRM3 antagonist, to treat OAB. TARGET/MARKER/PATHWAY: Muscarinic acetylcholine receptor M3...
...Fraser J. Sim, University at Buffalo, Buffalo, N.Y. email: fjsim@buffalo.edu Hongjiang Li University at Buffalo Muscarinic acetylcholine receptor M3...
BioCentury | Aug 3, 2018
Finance

Karuna’s CNS double play

...acetylcholine receptor M1 (CHRM1; HM1) and M4, with trospium chloride, an antagonist of M2 and M3...
...chloride Karuna Pharmaceuticals Inc. Muscarinic acetylcholine receptor M1 (CHRM1) (HM1) Muscarinic acetylcholine receptor M2 (CHRM2) (HM2) Muscarinic acetylcholine receptor M3...
BioCentury | Aug 3, 2018
Financial News

Karuna raises $42M series A

...Co. Karuna Pharmaceuticals Inc. Muscarinic acetylcholine receptor M1 (CHRM1) (HM1) Muscarinic acetylcholine receptor M2 (CHRM2) (HM2) Muscarinic acetylcholine receptor M3...
Items per page:
1 - 10 of 174